In MS treatment, other drugs such as anti-B cell Mabs (anti-CD20 Mabs), dimethyl fumarate, or fingolimod had an increase of PML risk, but far less than NAT (52). Here, BRD2 is linked to progressive multifocal leukoencephalopathy.